Home  /  Resource Library  /  Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma

Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma

Results of a study examining orelabrutinib combined with rituximab and methotrexate for treatment of PCNSL.